BGI Genomics Receives EUA for SARS-CoV-2 Test Kit

BGI Genomics Co. and its U.S. subsidiary BGI Americas Corp., received Emergency Use Authorization (EUA) from the U.S. FDA for its RT-PCR kit for detecting SARS-CoV-2.

BGI's highly sensitive test can return results within three hours and is intended for the qualitative detection of SARS-CoV-2, the virus that causes COVID-19 disease, in bronchoalveolar lavage fluid (BALF) and throat swabs.

"The authorization of our diagnostic test for COVID-19 in the US will provide high-quality, high-volume testing capabilities to the US, and enable medical professionals to respond quickly to diagnose patients, preventing further spread of infection," said Ye Yin, CEO of BGI Genomics.

Register as Visitor to CPhI China 2020!

-----------------------------------------------------------------------
Editor's Note:

En-CPhI.CN is a vertical B2B online trade platform serving the pharmaceutical industry,

for any copyright disputes involved in the articles,

please email: Julia.Zhang@imsinoexpo.com to motify or remove the content.